Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dicerna and PBL Sign Agreement for Baulcombe & Hamilton RNAi Patents

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Dicerna Pharmaceuticals, Inc. (Dicerna) and Plant Bioscience Limited (PBL), announced that they have entered an agreement for a non-exclusive licence to PBL’s RNAi intellectual property estate.

PBL will grant Dicerna a world-wide, non-exclusive license to the Baulcombe patents (U.S. Patent Nos. 8,097,710; 8,258,285; 8,299,235 and 8,263,569) for use in the field of human therapeutics.  Financial terms were not disclosed.

“We are pleased to add the Baulcombe patents to our expanding intellectual property portfolio,” said Douglas M. Fambrough, CEO of Dicerna.  “We have continued to innovate and advance our DsiRNA and EnCore technologies, allowing us to develop innovative programs against previously undruggable targets.  Dicerna’s programs, along with those of our partners, means we are moving forward on multiple fronts to bring new options to patients via well-known and powerful mechanisms.”

PBL’s Managing Director, Dr. Jan Chojecki, stated, “We are delighted to add Dicerna as our partner in the development of RNAi therapeutics. Dicerna is currently advancing an exciting RNAi-based therapeutic oncology candidate into the development stage.  This agreement further endorses the strength of our patent estate in the RNAi field and we look forward to working with other partners in therapeutic applications, as well as in research reagents, diagnostics and of course agricultural applications of this pivotal technology.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dicerna Reports Progress with GalNAc-DsiRNA-EX-Conjugates
Dicerna has presented preclinical data suggesting the feasibility of its proprietary GalNAc-DsiRNA-EX-Conjugate technology in enabling direct delivery of RNAi-based therapy to the liver via subcutaneous (SC) or intravenous (IV) injection.
Thursday, March 03, 2016
Dicerna Announces Potent, Durable Knockdown of Gene Expression in Non-human Primates
The company, a leader in the development of RNA interference (RNAi) therapeutics, presented preclinical data demonstrating the feasibility of its proprietary DsiRNA-EX Conjugate-mediated delivery technology.
Thursday, May 07, 2015
Dicerna Pharmaceuticals Appoints Life Sciences Executive James B. Weissman to Chief Business Officer
Mr. Weissman joins Dicerna with more than 25 years in the life sciences industry and will be responsible for corporate development, strategy and other operational functions.
Thursday, January 05, 2012
Scientific News
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Cancer Cells Coordinate to Form Roving Clusters
Rice University scientists identify ‘smoking gun’ in metastasis of hybrid cells.
Poliovirus Therapy Wins 'Breakthrough' Status
FDA decision will fast-track research on breakthrough Duke brain cancer therapy.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
New Treatment for Pancreatic Cancer
Researchers at Purdue University have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!